SantoSolve AS   Report issue

For profit Phase 3
Founded: Oslo Norway (1994)
Status: Left NME R&D (2019)

Organization Overview

First Clinical Trial
2007
NCT00592098
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2009

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (1)

strontium-89 (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Osteoarthritis (Phase 3)

Osteoarthritis, Knee (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 1